2-DG 63 mg + SOC | SOC1 | 2-DG 90 mg + SOC | 2-DG 126 mg + SOC | SOC2 | Pooled SOC (SOC1 + SOC2) | ||
---|---|---|---|---|---|---|---|
Time (days) to achieve SpO2 ≥ 94% (on two consecutive assessments on room air, at sea level) | N | 22 | 22 | 22 | 21 | 22 | 44 |
Median (days) | 5 | 5 | 2.5 | 3 | 5 | 5 | |
HR (95% CI)a | 1.277 (0.658, 2.477) | – | 2.3 (1.14, 4.642) | 0.975 (0.494, 1.925) | – | – | |
P-value a | 0.4698 | – | 0.0201 | 0.9415 | – | – | |
Time (days) to discharge | Median (days) | 12 | 11 | 8 | 11 | 10 | 10 |
HR (95% CI)a | 0.791 (0.416, 1.504) | – | 2.238 (1.065, 4.703) | 0.679 (0.334, 1.38) | – | – | |
P-value a | 0.4746 | – | 0.0336 | 0.2847 | – | – | |
Time (days) to clinical recoveryb | Median (days) | 4.5 | 5 | 3 | 4 | 6 | 5 |
HR (95% CI)a | 0.985 (0.526, 1.846) | – | 3.837 (1.853, 7.944) | 1.881 (0.922, 3.838) | – | – | |
P-value a | 0.9629 | – | 0.0003 | 0.0824 | – | – | |
Time (days) to vital signs normalisationc | Median (days) | 7 | 7 | 5 | 10 | 8 | 7 |
HR (95% CI)a | 0.889 (0.472, 1.674) | – | 4.341 (1.669, 11.294) | 1.024 (0.418, 2.511) | – | – | |
P-value | 0.7162 | – | 0.0026 | 0.958 | – | – | |
Time (days) to achieve 2 points improvement on WHO clinical progression scale | Median (days) | 11 | 10.5 | 5 | 5 | 6 | 8 |
HR (95% CI)a | 0.624 (0.318, 1.224) | – | 1.763 (0.924, 3.363) | 1.183 (0.63, 2.221) | – | – | |
P-valuea | 0.1702 | – | 0.0852 | 0.6021 | – | – | |
Time (days) to achieve 1 point improvement on WHO clinical progression scale | Median (days) | 5.5 | 6 | 4 | 3 | 5 | 5 |
HR (95% CI) a | 1.414 (0.71, 2.818) | – | 1.483 (0.78, 2.822) | 1.301 (0.697, 2.427) | – | – | |
P-valuea | 0.3247 | – | 0.2297 | 0.409 | – | – |